Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

Abstract Background The effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) by age group (< 65, 65–74, and ≥ 75 years) are uncertain. We examined retention rates reflecting the effectiveness and safety of bDMARDs in actual clinical practice for clarifying optima...

Full description

Bibliographic Details
Main Authors: Akio Kawabe, Kazuhisa Nakano, Satoshi Kubo, Takeshi Asakawa, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Biological disease-modifying antirheumatic drugs
Retention rate
Inverse probability of treatment weighting
Generalized propensity score
Online Access:http://link.springer.com/article/10.1186/s13075-020-02233-9

Internet

http://link.springer.com/article/10.1186/s13075-020-02233-9

Similar Items